Trial Profile
Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms DeepSwitch
- 25 Apr 2017 Status changed from recruiting to discontinued as no more participants taking atripla.
- 20 May 2015 New trial record
- 19 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.